NCT06845202
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Active, Not Recruiting
PHASE1Ages 18–75InterventionalTreatmentAlnylam Pharmaceuticals
~105 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:ALN-4324Placebo
At a glance
Recruiting sites
0 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A: Frequency of Adverse Events (AEs)
Measured over Up to 9 months
+1 more outcome measured
Conditions
Where it's being run
22 sites across 11 statesArgentina4
Poland4
Canada3
Chile3
Texas2
California1
District of Columbia1
Florida1
Study leadership
- Medical Director · STUDY_DIRECTOR · Alnylam Pharmaceuticals
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Has a body mass index (BMI) of ≥27 kg/m\^2 and \<40 kg/m\^2
Is an adult patient with a confirmed diagnosis of T2DM
Has a hemoglobin A1c (HbA1c) ≥7% to \<10.5%
Has a BMI of ≥25 kg/m\^2 and \<45 kg/m\^2
Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i)
Exclusion
Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i
What this trial measures
- Part A: Frequency of Adverse Events (AEs)Up to 9 months
- Part B: Frequency of Adverse EventsUp to 12 months